Seres Therapeutics, Inc. (MCRB) Stock Score, Valuation & Financial Research

Seres Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MCRB

Seres Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.90. These figures are a research snapshot, not a buy or sell recommendation.

What Seres Therapeutics, Inc. does

Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Seres Therapeutics is a late-stage biotechnology company focused on developing microbiome-based therapeutics. The company generates revenue primarily through research and development collaborations and licensing agreements, as it currently does not have commercialized products generating significant recurring product sales.

Products and services

  • The company develops a pipeline of live biotherapeutic products, including SER-155 for allo-HSCT patients and SER-603 for inflammatory bowel disease, utilizing a proprietary platform for drug discovery and manufacturing.

Customer types

Clinical research institutions; Pharmaceutical and biotechnology collaborators.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials; specific supplier names are unnamed. Source

Business relationships and partnerships

  • CARB-X — Awarded a grant to support the development of an oral liquid formulation of SER-155 for medically vulnerable patient populations. Source

Business strengths to evaluate

  • Proprietary microbiome therapeutic platform and manufacturing capabilities Source

Business risks and research considerations

  • Dependence on third-party manufacturers and clinical trial collaborators Source
  • History of operating losses and need for additional capital Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MCRB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.90
Market capitalization:
28.08M (currency not supplied)
Revenue:
USD 1.88M
Net income:
USD -22.46M
Free cash flow:
USD 865K
Cash:
USD 15.59M
Total debt:
USD 56.64M
EPS:
USD -2.42

What stands out

  • Reported year-over-year revenue growth is +138.7%.
  • Free cash flow is USD 865K, positive for the stored period.
  • The balance sheet shows USD 15.59M of cash versus USD 56.64M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is 45.9% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -1192.9% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 41.05M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MCRB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can MCRB sustain its current revenue growth while also converting that growth into durable profit and free cash flow?
  • Is MCRB's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
  • Is MCRB's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for MCRB to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of MCRB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research MCRB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.